Relmada Therapeutics Inc (RLMD) - Forward Price-to-Revenue Multiple
Relmada Therapeutics (RLMD) relies on outsourcing production and testing to maintain R&D flexibility. High barriers to entry are created by REL-1017 patents under strict FDA oversight. The company's fate is tied to the success of trials and the rate of capital expenditure. This forward price-to-sales chart visualizes these trends, and the current metric has reached the level of .
Comprehensive metric breakdowns and analytics for Relmada Corp (RLMD)
- stock price and consensus target price:
- market capitalization indicators:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Relmada Therapeutics|RLMD - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Relmada Therapeutics|RLMD - Company Aggregate Debts|Debt to Book Capitalization Ratio Relmada Corp|RLMD - Long-Term Liabilities|Company Short-Term Debts Relmada Therapeutics|Quick Liquidity Indicator relmada.com
- financial results and valuation multiples details:
RLMD - Net Profit|Future Profit Relmada Therapeutics|RLMD - Market Price to Net Income Ratio|Forward P/E Multiple Relmada|RLMD - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Relmada Corp|RLMD - Operating profit before deduction of amortization|Earnings per share for the last twelve months Relmada Therapeutics|RLMD - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months relmada.com|RLMD - Earnings per share increase in current year|Net earnings per share growth forecast for next year Relmada Therapeutics
- company sales and revenue statistics:
Fundamental company analysis:RLMD (Relmada Therapeutics, Inc.)
The dynamics of this multiple reflect market expectations regarding future sales and the business's ability to maintain its capitalization amid changing external conditions. Since Relmada Therapeutics (RLMD) is in the clinical trial stage and has no current revenue, the company's forward P/S chart demonstrates a speculative valuation of potential revenue, which currently depends entirely on the efficiency of raising external capital.
Direct competitors
Biogen - Forward Price-to-Revenue Multiple|Forward Price to Sales NBIX|RGC: Forward Price-to-Revenue Multiple|Axsome Corp - Price to Expected Revenue Ratio|ACAD: Forward P/S Multiple|xenon-pharma.com - Forward Price to Sales|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Supernus Pharmaceuticals, Inc. SUPN|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|DNLI (Denali Corp) - Forward Price to Sales|Forward P/S Multiple HRMY (Harmony Biosciences)|Forward P/S Multiple biohavenpharma.com BHVN|AMLX - Price-to-Projected Revenue Ratio|Future Price to Revenue TRVI|PRAX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Anavex Life Sciences Corp (AVXL)|Forward Price-to-Revenue Multiple CBLL|Forward P/S Multiple Prothena Corporation|Forward Price-to-Revenue Multiple ALEC (Alector, Inc.)|Price to Expected Revenue Ratio ANNX|Forward P/S Multiple OMER (Omeros)|Market Cap to Expected Sales Ratio Neurogene Therapeutics (NGNE)|AC Immune - Forward P/S Multiple|voyagertherapeutics.com (VYGR) - Forward Price-to-Revenue Multiple|Neumora Therapeutics, Inc. (NMRA) - Price-to-Projected Revenue Ratio|SCLX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Tevogen Bio Holdings, Inc.|ACOG: Forward Price to Sales|Price-to-Projected Revenue Ratio Cognition Therapeutics (CGTX)|Price-to-Projected Revenue Ratio IKT (inhibikase.com)|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|ASRT - Forward Price-to-Revenue Multiple|Coya - Forward P/S Multiple|VTGN (Vistagen Therapeutics) - Market Cap to Projected Revenue|ovidrx.com (OVID) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ABOS|CRVO (CervoMed) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Alterity Therapeutics Ltd ATHE|Forward Price-to-Revenue Multiple CLNN (Clene Inc.)|Forward P/S Multiple pepgen.com (PEPG)|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|Forward Price to Sales ANVS|GRCE - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Firefly Neuroscience, Inc.|anewmeds.com (KLTO) - Price-to-Projected Revenue Ratio|NeuroSense Therapeutics Ltd. - Forward Price to Sales|RVPH (Reviva Pharmaceuticals) - Forward P/S Multiple|Market Cap to Future Revenue Ratio MetaVia, Inc. MTVA|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|Price-to-Projected Revenue Ratio HSDT (heliusmedical.com)|Price-to-Projected Revenue Ratio Passage Bio PASG|NEUP - Forward Price-to-Revenue Multiple|Minerva Neurosciences - Forward P/S Multiple|ATHA - Forward P/S Multiple|ADXN: Forward P/S Multiple|Market Cap to Projected Revenue ALZN|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|Forward P/S Multiple Protagenic|Forward Price-to-Revenue Multiple KTTA (Pasithea Therapeutics)|CRGT (cortigent.com) - Forward Price to Sales|Avenue Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio BCLI (Brainstorm Cell Therapeutics Inc.)|Cara Therapeutics, Inc - Forward P/S Multiple|Forward Price to Sales CHRO (Chromocell)|ELYM: Forward P/S Multiple|Market Cap to Future Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|Price-to-Projected Revenue Ratio Longboard Pharmaceuticals, Inc.|MRNS: Forward Price to Sales|Forward P/S Multiple NKGN|Forward P/S Multiple NeuroBo Pharma (NRBO)|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|SNPX (synaptogen.com) - Future Price to Revenue|Trevena - Forward P/S Multiple|Market Cap to Future Revenue Ratio Vigil Neuroscience|WENA (Anew Medical) - Forward Price-to-Revenue Multiple|Cerevel Corp (CERE) - Forward P/S Multiple
